Loading Complete
Melhem Mohammad Solh

Melhem Mohammad Solh, MD

Blood and Marrow TransplantHematology Oncology

Top Doctor
Accepting New Patients

Highlights

Languages

  • English

Gender

Male

About Melhem Mohammad Solh

About the Provider

Dr. Solh is board-certified in the subspecialties of medical oncology and hematology and is a Northside Hospital Blood and Marrow Transplant and Leukemia and Immunotherapy Program physician. He is the medical director for the Cellular Therapy Program at Northside Hospital. Since 2019, Dr. Solh has been recognized by his peers as one of Castle Connolly's Top Doctors in Atlanta in his specialty.

Awards

  • Castle Connolly’s Top Doctors, 2019 - Present

Hospital Affiliations

Interpreter Services

The information on languages spoken was reported by the provider and may not have been verified by Northside Hospital. It may also include languages spoken by office staff. Interpretation services, including American Sign Language, are available upon request.

Clinical Interests

  • Blood & Marrow Transplant
  • Acute Leukemia
  • Relapsed & Refractory Hematological Blood Cancers 
  • Relapsed & Refractory Malignant Melanoma 
  • Immunotherapy (CAR T-cell, Tumor Infiltrating Lymphocyte (TIL) and Immune Effector Cell Therapies) 

Expertise

Education

  • Fellowship: University of Minnesota Medical School, Hematology-Oncology, 2011
  • Residency: Wayne State University, Internal Medicine, 2008
  • Internship: Providence Hospital and Medical Center, 2005
  • Medical School: American University of Beirut Faculty of Medicine, 2003

Board Certifications

  • Hematology: American Board of Internal Medicine, 2011
  • Medical Oncology: American Board of Internal Medicine, 2011
  • Internal Medicine: American Board of Internal Medicine, 2008

Insurance

Search plans
  • Amerigroup: Medicaid product
  • Caresource: Marketplace Exchange product
  • Caresource: Medicaid product
  • Medicaid
  • Medicare
  • Peach State - Ambetter Exchange product
  • Peach State: Medicaid product
  • WellCare: Medicare product via Peach State